AssetMark’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
BP
AssetMark's PBE Position: Q3 2026 in Review
AssetMark opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q3 2026: 20 shares worth $1.95K. The stake represents ﹤0.01% of the portfolio and ranks #3060 among its holdings. This is a return to the name: AssetMark previously reported a position in PBE as recently as Q1 2026.
AssetMark first reported a position in PBE in Q4 2015 and has held it in 12 quarters since. The position peaked at $27.3K in Q1 2026. 106 funds tracked by Wall St. Rank hold PBE as of Q3 2026.
- AssetMark held 20 shares of Invesco Biotechnology & Genome ETF worth $1.95K as of Q3 2026.
- Invesco Biotechnology & Genome ETF was a new AssetMark position in Q3 2026.
- Invesco Biotechnology & Genome ETF made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3060 holding.
- AssetMark first reported a position in Invesco Biotechnology & Genome ETF in Q4 2015 and has held it in 12 quarters since.
- AssetMark's Invesco Biotechnology & Genome ETF position peaked at $27.3K in Q1 2026.
- 106 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.